Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Fineline Cube Dec 14, 2025
Company Deals

InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program

Fineline Cube Dec 14, 2025
Company Deals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

Fineline Cube Dec 13, 2025
Company Deals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

Fineline Cube Dec 13, 2025
Company Deals

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

Fineline Cube Dec 13, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Fineline Cube Dec 14, 2025
Company Drug

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment

Fineline Cube Dec 14, 2025
Company Deals

Junshi Biosciences Licenses PD-1 Inhibitor Tuoyi to Hikma MENA FZE

Fineline Cube Dec 26, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a licensing agreement with UK-headquartered Hikma...

Company Deals

Shanghai Pharmaceuticals Secures Exclusive Rights for Shionogi’s Ensitrelvir in China

Fineline Cube Dec 26, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has announced an import and distribution agreement with Japan-based...

Company Drug

WHO Approves Sinovac’s CoronaVac for Children Aged 3 and Above

Fineline Cube Dec 23, 2022

The World Health Organization (WHO) has lowered the age limit for Sinovac Biotech Ltd’s (NASDAQ:...

Policy / Regulatory

NHSA Orders Investigation into Unreasonable Medical Insurance Restrictions

Fineline Cube Dec 23, 2022

The National Healthcare Security Administration (NHSA) has released a notification to medical insurance departments across...

Company Drug

Fosun Pharma’s Avatrombopag Receives NMPA Review for Chronic ITP Indication

Fineline Cube Dec 23, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that another...

Company Deals

Nanjing Pharmaceutical to Acquire Majority Stakes in Three Jiangsu Subsidiaries

Fineline Cube Dec 23, 2022

China-based Shanghai-listed Nanjing Pharmaceutical Co., Ltd (SHA: 600713) is set to acquire a respective 55%,...

Company Deals

MSD and Kelun Biotech Ink Record-Breaking ADC Deal

Fineline Cube Dec 23, 2022

Merck, Sharp & Dohme (MSD, NYSE: MRK) has set a new benchmark for the largest...

Policy / Regulatory

NMPA and GAC Release Notification on Import and Export Management of Narcotic Drugs

Fineline Cube Dec 23, 2022

The National Medical Products Administration (NMPA) and the General Administration of Customs (GAC) have released...

Company Drug

Shyndec’s Generic Cytosar-U Gains Marketing Approval in China

Fineline Cube Dec 23, 2022

China-based Shanghai Shyndec Pharmaceutical Co., Ltd (SHA: 600420) has announced that its generic version of...

Company Medical Device

Sino Medical Sciences’ NC Rockstar Catheter Approved by US FDA

Fineline Cube Dec 23, 2022

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving market approval from the...

Company Drug

Antengene Files for Xpovio Approval in Macau, Malaysia, and Thailand

Fineline Cube Dec 23, 2022

Antengene Corp., Ltd (HKG: 6996) has announced market filings for its Xpovio (selinexor) in Macau,...

Drug

Eisai and Biogen Initiate BLA in China for Alzheimer’s Therapy Lecanemab

Fineline Cube Dec 23, 2022

Japan-based Eisai Co., Ltd (TYO: 4523) and its US co-development partner Biogen Inc. (NASDAQ: BIIB)...

Company Deals

Qitan Tech Raises RMB 700 Million in Series C Financing Led by Meituan

Fineline Cube Dec 23, 2022

Qitan Tech, a nanopore gene sequencer maker based in Chengdu, has reportedly raised RMB 700...

Company Drug

Kanghong’s Escitalopram Oral Solution Receives NMPA Marketing Approval

Fineline Cube Dec 23, 2022

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving marketing approval from...

Company Drug

Tonghua Dongbao Receives NMPA Approval for THDBH151 Clinical Study in Gout and Hyperuricemia

Fineline Cube Dec 23, 2022

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has announced receiving approval from the National Medical Products...

Company Deals

Innovent Biologics Announces Strategic Partnerships to Form Tumor Diagnosis and Treatment Alliance

Fineline Cube Dec 23, 2022

China-based Innovent Biologics (HKG: 1801) has announced a series of strategic partnerships with compatriot firms...

Company Drug

BioNTech Ships First COVID-19 Vaccine Batches to China

Fineline Cube Dec 22, 2022

BioNTech is reportedly in the process of shipping the first batches of its COVID-19 vaccines...

Company Drug

Merck Launches Noxafil in China for Antifungal Treatment

Fineline Cube Dec 22, 2022

US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) has announced the official market launch...

Company Drug

Hinova’s PROTAC Drug HP518 Accepted for FDA Review in mCRPC

Fineline Cube Dec 22, 2022

China-based biopharma Hinova Pharmaceuticals has announced that a clinical trial filing for its androgen receptor...

Company Drug

Fosun Kite’s CAR-T Therapy FKC889 Approved for Clinical Trials in China

Fineline Cube Dec 22, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its...

Posts pagination

1 … 514 515 516 … 597

Recent updates

  • Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation
  • Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal
  • Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial
  • Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment
  • InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation

Company Deals

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Company Drug

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Company Drug

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.